Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference, or RNAi, therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead’s leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Sarepta price target lowered to $75 from $80 at H.C. Wainwright
- Arrowhead price target lowered to $24 from $27 at Bernstein
- Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance
- Dell and HP forecasts spark selloffs: Morning Buzz
- Sarepta price target lowered to $202 from $205 at Needham